TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03033810

Intervention type: DEVICE
Intervention: Fractional flow reserve and instantaneous wave-free ratio
Description: 1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance.
Study: NCT02450539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study: NCT02597374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: A 45 mn EEG will be performed in each participants during action and action observation of each hand.
Study: NCT01215279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 100 mg oral treatment once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD2423
Description: Oral treatment once daily for 28 days
Study: NCT01576705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
Study: NCT02421653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP90
Description: 90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP45
Description: 45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IODISED OIL
Description: 200 mg iodine oil capsule; oral route; once at study start
Study: NCT00096408

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Abdominal Hysterectomy
Description: For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy
Description: The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
Study: NCT03539796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional epidurals (EPI)
Description: Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined-spinal epidural technique (CSE)
Description: Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
Study: NCT04431089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M
Description: Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Study: NCT01894815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram oxalate
Description: The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS + Placebo Pill
Description: This group receives sham tDCS and placebo pill.
Study: NCT00776685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
Study: NCT04295265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone message
Description: Receive daily whatsapp/ SMS message to remind the drug intake
Study: NCT00776685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions
Description: Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
Study: NCT04739865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open label
Study: NCT01966432

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral to Treatment
Description: Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
Study: NCT00870493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg daily oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 300 mg daily oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: starch tablet, 300 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: starch tablet, 300 mg/day
Study: NCT00408681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00863187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: b cell depletion
Study: NCT02062931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Preparation and Injection
Description: Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue.
Study: NCT02610283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1002
Description: IV injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study: NCT02764840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic dynamometer
Description: In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic tube
Description: In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
Study: NCT02156700

Intervention type: PROCEDURE
Intervention: Shear wave elastography
Description: Measurement of tumor stiffness by Shear wave elastography - SWE™
Study: NCT02534337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4
Description: Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Study: NCT02732158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Products
Description: a sachet containing AN777and amino acids; a carotenoid capsule
Study: NCT03972371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ProVee Urethral Expander System
Description: The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
Study: NCT01268397

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation with a volar plate
Description: flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed reduction and plaster treatment
Description: closed reduction, below elbow plaster cast, semicircular for 5 week
Study: NCT02792777

Intervention type: OTHER
Intervention: Interviews
Description: Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.

Intervention type: OTHER
Intervention: Concept Mapping (CM)
Description: The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group.
Study: NCT03497962

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Broncho-alveolar lavage to obtain alveolar macrophages

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Broncho-alveolar lavage to obtain alveolar macrophages
Study: NCT04301453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Scent
Description: Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
Study: NCT03731715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
Study: NCT01966432

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Intervention
Description: Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
Study: NCT03731715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
Study: NCT03556696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI-REMI-loop
Description: experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil pK/pD target administration device
Description: standard practice, remifentanil administration using Minto's pK/pD model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANI monitor
Description: ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target
Study: NCT02255838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscope reusable (Storz 8402 2x)
Description: Bronchoscopy and alveolar lavage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscope disposable (aScope 4)
Description: Bronchoscopy and alveolar lavage
Study: NCT04230577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real LED Intervention
Description: A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real LED Intervention
Description: A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LED Intervention
Description: A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
Study: NCT01032278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
Study: NCT00647023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1000 mg metformin x 2 daily during 8 months
Study: NCT02599012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject®
Description: intravenous Ferinject 1000mg injection
Study: NCT01745055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 (tofacitinib)
Description: CP-690,550 30 mg q12h for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: individual dose of methotrexate (stably dosed)
Study: NCT00802477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of autologous blood products.
Description: Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
Study: NCT01111188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2
Study: NCT00682838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management
Description: Self-management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management
Description: Self-management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemonitored care
Description: Telemonitored care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitored care
Description: Telemonitored care
Study: NCT00802477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Modified Radical Mastectomy
Description: Mastectomy per standard procedure without the application of autologous blood products.
Study: NCT01377467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Prolia)
Description: 60 mg s.c. injection at baseline and after 6 months
Study: NCT02628730

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using ThermoCool® SmartTouch® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.

Intervention type: DEVICE
Group type: OTHER
Intervention: RFA ablation data comparison
Description: Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
Study: NCT00513630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01696214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 250 mg/salmeterol 50 mg
Description: Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10mg
Description: Participants will be assigned to montelukast once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline 400 mg
Description: Participants will be assigned to theophylline once a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipratropium
Description: Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
Study: NCT00465569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cow's milk powder
Description: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02648230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St. Jude Medical Pressure Wire
Description: FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACIST Navvus Microcatheter
Description: FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
Study: NCT03013127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy.